Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

RAS mutations are frequent in extramedullary AML and drive the tissue infiltration of leukemic cells via the induction of jaml

Blood (2025) 146 (Supplement 1): 659.

https://doi.org/10.1182/blood-2025-659

Published: 2025

Journal Articles

Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria

Blood (2025) 146 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2025-4584

Published: 2025

Journal Articles

Sequential Dosing of Next-Generation IMA203CD8 TCR-T-Cell Therapy Targeting PRAME in Combination with BRAF-/MEK-Inhibition in a Melanoma Patient with Progressive Disease - a Case Report

Friederike Schmitz, Martin Schumacher, Annkristin Heine, Annette Busch, Mario Heine, Julian A. Luetkens, Jennifer Landsberg, Niklas Schäfer, Oliver Ebert, Robert Zeiser, John G. Gribben, Peter Brossart, Tobias A.W. Holderried

Blood (2024) 144 (Supplement 1): 7194.

https://doi.org/10.1182/blood-2024-194461

Published: 2024

Journal Articles

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Konstantinos Christofyllakis, Igor Age Kos, Bettina Altmann, Viola Poeschel, Stephanie Maurer, Vadim Lesan, Jörg-Thomas Bittenbring, Dominic Kaddu-Mulindwa, Zanir Abdi, Manfred Ahlgrimm, Sarah Altmeyer, Octavian Fleser, Gerhard Held, Maike Nickelsen, Martin Dreyling, Florian Zettl, Christian Buske, Georg Lenz, Bertram Glass, Björn Chapuy, Norbert Schmitz, German Ott, Reiner Siebert, Andreas Viardot, Florian Scherer, Roland Schmitz, Andreas Rosenwald, Dirk Hellwig, Nina Neuendorff, Theodoros Vassilakopoulos, Chrysoula Doxani, Pascal Blatt, Oguzhan Nakisli, Susanne Schmidt, Tobias Gaska, Börge Arndt, Matthias Mueller, Hanno Maximilian Witte, Martin Bentz, Volkmar Boehme, Heinz Kirchen, Markus Loeffler, Boris Kubuschock, Niklas Gebauer, Rolf Mahlberg, Julian Topaly, Alexander Bott, Kai Wille, Ralf Ulrich Trappe, Mathias J. Rummel, Gerald Illerhaus, Franziska Brunner, Martin Klump, Ulrich Kaiser, Swen Wessendorf, Iordanis Deligiannis, Bert Hildebrandt, Alexander Kiani, Thomas Illmer, Gabriele Prange-Krex, Kristina Lerch, Matthias Sandmann, Sebastian Broeckling, Uwe Martens, Bastian von Tresckow, Annkristin Heine, Holger F. Hebart, Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, Marita Ziepert

Blood (2024) 144 (Supplement 1): 4498.

https://doi.org/10.1182/blood-2024-199685

Published: 2024

Journal Articles

The JAK Inhibitor Ruxolitinib Impairs Dendritic Cell Migration Via Off-Target Inhibition of Rock

Janna Rudolph, Annkristin Heine, MD, Thomas Quast, Waldemar Kolanus, Peter Brossart, MD, Dominik Wolf, MD

Blood (2015) 126 (23): 3423.

https://doi.org/10.1182/blood.V126.23.3423.3423

Published: 2015

Journal Articles

Influence of G-CSF Mobilization and Liquid Storage Time on Post-Thaw Recovery of Lymphocyte Subpopulations and CD34 + Cells in Cryopreserved Apheresis Products

Christina Berens, MD, Annkristin Heine, MD, Jens Mueller, PhD, Johannes Oldenburg, Dominik Wolf, MD, Bernd Poetzsch, Prof., Heiko Ruehl, MD

Blood (2015) 126 (23): 4307.

https://doi.org/10.1182/blood.V126.23.4307.4307

Published: 2015

Journal Articles

A party of three: iNKT cells in GVHD prevention

Annkristin Heine, Peter Brossart

Blood (2015) 125 (22): 3374–3375.

https://doi.org/10.1182/blood-2015-04-636282

Published: 2015

Journal Articles

The JAK Inhibitor Ruxolitinib Substantially Affects NK Cells in MPN Patients

Kathrin Schönberg, PhD, Janna Rudolph, Maria Vonnahme, Isabelle Cornez, PhD, Sowmya Parampalli Yajnanarayana, Walter Verbeek, MD, Steffen Koschmieder, MD, Tim H. Brümmendorf, MD, Peter Brossart, MD, Annkristin Heine, MD, Dominik Wolf, MD

Blood (2014) 124 (21): 3169.

https://doi.org/10.1182/blood.V124.21.3169.3169

Published: 2014

Journal Articles

Osteoactivin Mediates the Inhibitory Effects of Myeloid Derived Suppressor Cells

Stefanie Andrea Erika Held, PhD, Annkristin Heine, MD, Solveig Daecke, Anita Bringmann, Peter Brossart, MD

Blood (2014) 124 (21): 2745.

https://doi.org/10.1182/blood.V124.21.2745.2745

Published: 2014

Journal Articles

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Annkristin Heine, Peter Brossart, Dominik Wolf

Blood (2013) 122 (23): 3843–3844.

https://doi.org/10.1182/blood-2013-10-531103

Published: 2013

Journal Articles

Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival

Susanne M Rittig, MD, Maik Häntschel, MD, Katrin J Weimer, MD, Annkristin Heine, MD, Martin R Müller, MD, PhD, Wolfram Brugger, MD, Marius Horger, MD, Olga Maksimovic, MD, Arnulf Stenzl, MD, Ingmar Hoerr, Hans-Georg Rammensee, Tobias A.W. Holderried, MD, Lothar Kanz, MD, Steve Pascolo, Peter Brossart, MD

Blood (2013) 122 (21): 1040.

https://doi.org/10.1182/blood.V122.21.1040.1040

Published: 2013

Journal Articles

Ruxolitinib Inhibits Dendritic Cell Function By Interfering With The MAP-Kinase/NF-Kb Signalling Pathways

Stefanie AE Held, PhD, Annkristin Heine, MD, Dominik Wolf, MD, Peter Brossart, MD

Blood (2013) 122 (21): 3463.

https://doi.org/10.1182/blood.V122.21.3463.3463

Published: 2013

Journal Articles

CD4 + T Cell Functions Are Potently Suppressed By The Janus Kinase 1/2 (JAK1/JAK2) Inhibitor Ruxolitinib

Sowmya Parampalli Yajnanarayana, Isabelle Cornez, PhD, Annkristin Heine, MD, Peter Brossart, MD, Dominik Wolf, MD

Blood (2013) 122 (21): 2281.

https://doi.org/10.1182/blood.V122.21.2281.2281

Published: 2013

Journal Articles

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

Annkristin Heine, Stefanie Andrea Erika Held, Solveig Nora Daecke, Stephanie Wallner, Sowmya Parampalli Yajnanarayana, Christian Kurts, Dominik Wolf, Peter Brossart

Blood (2013) 122 (7): 1192–1202.

https://doi.org/10.1182/blood-2013-03-484642

Published: 2013

Includes: Supplemental data

Journal Articles

Generation of Immunosuppressive Antigen Presenting Cells with the Phenotype and Function of Myeloid Derived Suppressor Cells

Stefanie AE Held, Annkristin Heine, MD, Julia Wolf, Solveig Daecke, Anita Bringmann, PhD, Peter Brossart, MD

Blood (2012) 120 (21): 1032.

https://doi.org/10.1182/blood.V120.21.1032.1032

Published: 2012

Journal Articles

The Imatinib and Nilotinib Induced Modulation of the Proteasomal Activity and Antigen Processing in Chronic Myeloid Leukemia Cells

Stefanie AE Held, Annkristin Heine, MD, Stefan Tenzer, PhD, Anita Bringmann, PhD, Hansjoerg Schild, MD, Prof., Christoph Driessen, MD, Peter Brossart, MD

Blood (2011) 118 (21): 2748.

https://doi.org/10.1182/blood.V118.21.2748.2748

Published: 2011

Journal Articles

Regulation of dectin-1–mediated dendritic cell activation by peroxisome proliferator–activated receptor-gamma ligand troglitazone

Grethe Kock, Anita Bringmann, Stefanie Andrea Erika Held, Solveig Daecke, Annkristin Heine, Peter Brossart

Blood (2011) 117 (13): 3569–3574.

https://doi.org/10.1182/blood-2010-08-302224

Published: 2011

Journal Articles

Interferon Gamma (IFNγ) Interferes with the Effects of Tyrosine Kinase Inhibitors (TKI) In CML Cells.

Stefanie AE Held, Anita Bringmann, PhD, Annkristin Heine, MD, Grethe Kock, Ruth-Miriam Körber, Nina Manon Seltmann, Peter Brossart, MD

Blood (2010) 116 (21): 3393.

https://doi.org/10.1182/blood.V116.21.3393.3393

Published: 2010

Journal Articles

Imatinib Mesylate and Nilotinib Affect the MHC-Class I Presentation by Modulating the Proteasomal Processing of Antigenic Peptides.

Stefanie Held, Stefan Tenzer, Thomas Rückrich, Karin von Schwarzenberg, Anita Bringmann, Annkristin Heine, Hansjörg Schild, Christoph Driessen, MD, Peter Brossart, MD

Blood (2009) 114 (22): 2169.

https://doi.org/10.1182/blood.V114.22.2169.2169

Published: 2009

Journal Articles

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro–transcribed MUC1 RNA

Daniela Dörfel, Silke Appel, Frank Grünebach, Markus M. Weck, Martin R. Müller, Annkristin Heine, Peter Brossart

Blood (2005) 105 (8): 3199–3205.

https://doi.org/10.1182/blood-2004-09-3556

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

RAS mutations are frequent in extramedullary AML and drive the tissue infiltration of leukemic cells via the induction of jaml

Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria

Sequential Dosing of Next-Generation IMA203CD8 TCR-T-Cell Therapy Targeting PRAME in Combination with BRAF-/MEK-Inhibition in a Melanoma Patient with Progressive Disease - a Case Report

Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL - an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

The JAK Inhibitor Ruxolitinib Impairs Dendritic Cell Migration Via Off-Target Inhibition of Rock

Influence of G-CSF Mobilization and Liquid Storage Time on Post-Thaw Recovery of Lymphocyte Subpopulations and CD34 + Cells in Cryopreserved Apheresis Products

A party of three: iNKT cells in GVHD prevention

The JAK Inhibitor Ruxolitinib Substantially Affects NK Cells in MPN Patients

Osteoactivin Mediates the Inhibitory Effects of Myeloid Derived Suppressor Cells

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival

Ruxolitinib Inhibits Dendritic Cell Function By Interfering With The MAP-Kinase/NF-Kb Signalling Pathways

CD4 + T Cell Functions Are Potently Suppressed By The Janus Kinase 1/2 (JAK1/JAK2) Inhibitor Ruxolitinib

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

Generation of Immunosuppressive Antigen Presenting Cells with the Phenotype and Function of Myeloid Derived Suppressor Cells

The Imatinib and Nilotinib Induced Modulation of the Proteasomal Activity and Antigen Processing in Chronic Myeloid Leukemia Cells

Regulation of dectin-1–mediated dendritic cell activation by peroxisome proliferator–activated receptor-gamma ligand troglitazone

Interferon Gamma (IFNγ) Interferes with the Effects of Tyrosine Kinase Inhibitors (TKI) In CML Cells.

Imatinib Mesylate and Nilotinib Affect the MHC-Class I Presentation by Modulating the Proteasomal Processing of Antigenic Peptides.

Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro–transcribed MUC1 RNA

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only